Latest news with #Bruker
Business Wire
11 hours ago
- Business
- Business Wire
Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity
BALTIMORE--(BUSINESS WIRE)--At the 73 rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) today announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns, and next-generation PepSep Advanced nLC columns, further enhancing robustness, sensitivity and proteome coverage in ultra-sensitive proteomics workflows. A. Bruker Introduces the proteoElute Next-Generation Nanoflow LC System for Robust, Ultra-Sensitive Proteomics Workflows with Real-time Monitoring Bruker announces the launch of the proteoElute, a state-of-the-art nanoflow liquid chromatography (LC) system designed for robust and ultra-sensitive multiomics applications. The proteoElute is ideal for single-cell proteomics, immunopeptidomics, microbiome metaproteomics profiling, and many other proteomics methods, ensuring reliable performance even with limited or very complex biological samples. The proteoElute features innovative TwinScape™ technology, which continuously monitors system health in real-time and runs background diagnostics. This proactive approach alerts users to potential issues, providing peace of mind when working with precious samples. Engineered for relentless reliability, the proteoElute includes biocompatible ceramic valves, new porous metal filters, and a proprietary trap column that together enhance robustness, chromatographic performance, and permit sample recovery. The new injector and needle wash system reduces carry-over by up to 3x, a critical advantage for confidently avoiding background signals when analyzing ultra-low input samples. W. Hayes McDonald, Associate Director in the Department of Biochemistry at Vanderbilt University, commented: ' The combination of the new proteoElute UHPLC platform along with updated PepSep Advanced columns and the proteoTrap column allows us the flexibility to perform any state-of-the-art proteomics workflow with highest performance. Its remarkable robustness gives us the confidence to execute all proteomics workflows at scale. ' B. Bruker Introduces PepSep Advanced Columns for Sharper nLC Peaks, Higher Sensitivity and Further Enhanced Peptide and Protein Identifications For highest sensitivity and performance of the proteoElute nLC system, Bruker introduces a new generation of PepSep Advanced nLC columns, engineered for precision, robustness, and speed. The columns deliver sharper peaks and higher-resolution separations for even deeper proteome coverage and consistent performance with challenging biological samples. In benchmark studies, the PepSep Advanced columns demonstrated approximately 20% improvements in peptide IDs and typically 10% improvements in protein IDs. Combined with CaptiveSpray Ionization (CSI) emitters, users can extend column lifetime by simply replacing the emitter—ensuring long-term performance and cost efficiency. PepSep columns provide the reliability and depth needed for analyzing complex tissue digests or low-input samples. Lynn Spruce, the Technical Director at the Children's Hospital of Philadelphia (CHOP-Penn) Proteomic Core Facility, said: 'The new PepSep Advanced columns have proven to be robust, and they consistently deliver reproducible chromatography. They produce sharper, more symmetrical peaks with no observable tailing, resulting typically in 7–8% increases in protein group identifications. Combined with the convenience of interchangeable emitters and reasonable pricing, it has become our go-to nLC column. It's essentially plug-and-play.' About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit
Yahoo
3 days ago
- Business
- Yahoo
Bruker Corporation to Present at the Jefferies Global Healthcare Conference
BILLERICA, Mass., May 30, 2025--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will participate in the Jefferies Global Healthcare Conference in New York City with a fireside chat presentation scheduled for Wednesday, June 4th, 2025 at 5:30 PM Eastern Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at A replay of the presentation will be posted in the "Events & Presentations" section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit View source version on Contacts Joe KostkaDirector, Investor RelationsBruker CorporationT: +1 (978) 313-5800E: Sign in to access your portfolio
Business Wire
3 days ago
- Business
- Business Wire
Bruker Corporation to Present at the Jefferies Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will participate in the Jefferies Global Healthcare Conference in New York City with a fireside chat presentation scheduled for Wednesday, June 4 th, 2025 at 5:30 PM Eastern Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at A replay of the presentation will be posted in the 'Events & Presentations' section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit
Business Wire
6 days ago
- Business
- Business Wire
Bruker Introduces Novel MOVE-T System for Transferable, Robust Milk and Liquid Dairy Analysis with FT-NIR Technology
ETTLINGEN, Germany--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced the launch of the MOVE-T, a state-of-the-art liquid dairy analyzer designed to elevate quality control standards in the dairy industry. Utilizing advanced Fourier Transform Near-Infrared (FT-NIR) technology, the MOVE-T provides unparalleled precision analyzing raw milk and other liquid dairy products, ensuring superior product quality and consistency. Tailored for the dairy industry and sectors processing liquid dairy products or plant-based drinks, it provides a robust tool for enhancing product quality and operational efficiency. The integration of FT-NIR technology with a wear-free quartz cell ensures high sensitivity, specificity, and transferability, making the MOVE-T an indispensable asset for modern dairy quality control. By leveraging the superior stability of FT-NIR technology over time and across instruments, the analyzer delivers precise and reliable results in accordance with ISO 21543 (IDF 201), setting a new benchmark in liquid dairy analysis and empowering producers to maintain consistent product quality. Katharina Baumgartner, Dairy Laboratory Specialist and long-time user of FT-NIR technology for milk analysis instruments at GOLDSTEIG Cheese Factories Bayerwald GmbH, commented: "We are thrilled with the new MOVE-T. The compact and integrated design seamlessly fits into our workflow. The transferability of methods is exceptionally good, as are the results for our key products in quality control. We are very excited about the market launch of the MOVE-T." Dr. Jörg-Peter Conzen, Vice-President of Bruker Optics, added, "The MOVE-T reflects our dedication and our commitment to innovation and analytical excellence. By providing the dairy industry with cutting-edge NIR technology, we are helping our customers achieve greater efficiency and product consistency. This launch completes our proven portfolio of dairy FT-NIR analyzers for lab and process control." About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nano analysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit
Yahoo
14-05-2025
- Business
- Yahoo
Bruker and 10x Genomics settle patent dispute
Bruker and 10x Genomics have agreed to settle a patent dispute relating to products originally developed by Nanostring, a company Bruker acquired in 2024. Under the settlement, whose financial terms have not been disclosed, the two companies have entered into global cross-license agreements for their patents. Additionally, all ongoing lawsuits and administrative proceedings in the US, Germany, and before the European Unified Patent Court, will be withdrawn. Filed by 10x in 2023, the initial lawsuit asserted that Nanostring's GeoMx Digital Spatial Profiler, a product that profiles the spatial distribution of RNA and protein expression across a tissue sample, infringed on seven patents. In November 2023, the district court of Delaware sided with 10x. Nanostring, a publicly listed company when the lawsuit was filed, went bankrupt in February 2024. Bruker acquired the company a month later for $392.6m, and inherited the lawsuit. On 23 December 2024, Delaware's district court issued its ruling on post-trial motions, in which damages of $31.6m were upheld, yet enhanced damages requested by 10x were declined. The final motion, an injunction request by 10x, was granted by the court, meaning that sales of GeoMx products to new customers in the US would be halted. At the time, Todd Garland, Bruker spatial biology division's president, said the company would 'promptly seek a stay' on any injunction ordered and looked forward to the appeal of its case being heard by the US Court of Appeals for the Federal Circuit. Commenting on the settlement agreement, Mark Munch, president of the Bruker Nano Group, said the company was happy to have the 'distraction and expense' of the legal cases behind it. 'We're pleased that we have reached a worldwide settlement with 10x, putting an end to all litigation between us,' Munch said. 'This is a great outcome for the scientific community, who can continue their work using Bruker's CosMx and GeoMx spatial biology platforms without concern that litigation could interfere with their advancements in oncology, neurobiology, and other fields of research.' "Bruker and 10x Genomics settle patent dispute" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
